Loading
Companies hold thousands of well-characterised drugs that could help rare cancers, but each request takes a year of legal negotiation. One standing agreement would unblock it.
Academic rare cancer groups routinely fail to obtain clinical-grade compound for investigator-initiated trials because material transfer and intellectual property negotiation exceed the capacity of small teams. A pre-negotiated multi-company access pool (standard terms, a single application route, an independent scientific review committee and mandatory data return) would industrialise access. Precedents exist in structural genomics consortia and in some public-private compound-sharing schemes.
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Secrecy and intellectual property block collaboration, Rare and paediatric cancers without markets.
Shares Rare cancers are not so rare: the rare cancer burden in Europe, European Society for Medical Oncology (ESMO), Rare and paediatric cancers without markets.
Shares Rare cancers are not so rare: the rare cancer burden in Europe, ClinicalTrials.gov, Rare and paediatric cancers without markets, National Cancer Institute (NIH).
Shares Rare cancers are not so rare: the rare cancer burden in Europe, ClinicalTrials.gov, Rare and paediatric cancers without markets.
Shares DrugBank & ChEMBL, ClinicalTrials.gov.
Shares ClinicalTrials.gov, Secrecy and intellectual property block collaboration.
Shares DrugBank & ChEMBL, The valley of death between lab and product.
Shares DrugBank & ChEMBL, Secrecy and intellectual property block collaboration.